

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10533744
	Filing Date		2005-05-04
	First Named Inventor	Brown	
	Art Unit	1624	
	Examiner Name	Emily B. Bernhardt	
	Attorney Docket Number	100886-1P US	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	4778789		1988-10-18	Fex et al.		
	2	5658908		1997-08-19	Chang et al.		
	3	5840896		1998-11-24	Van Belle et al.		
	4	7030124		2006-04-18	Chang et al.		
If you wish to add additional U.S. Patent citation information please click the Add button.							Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	20060030569		2006-02-09	Brown et al.		
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10533744
Filing Date		2005-05-04
First Named Inventor	Brown	
Art Unit	1624	
Examiner Name	Emily B. Bernhardt	
Attorney Docket Number	100886-1P US	

	1	2900810	DE		1980-07-24	Cassella AG		<input checked="" type="checkbox"/>
	2	2696744	FR		1994-04-15	Laboratoires Jacques Logeais		<input checked="" type="checkbox"/>
	3	215847	HU		1999-04-28	Janssen Pharmaceutica N.V.		<input type="checkbox"/>
	4	217619	HU		2000-03-28	Pharmacia & Upjohn		<input type="checkbox"/>
	5	7138230	JP		1995-05-30	Nippom Shoji KK		<input checked="" type="checkbox"/>
	6	9206971	WO		1992-04-30	Schering Corporation		<input type="checkbox"/>
	7	9626196	WO		1996-08-29	Schering Corporation		<input type="checkbox"/>
	8	0146263	WO		2001-06-28	AstraZeneca AB		<input type="checkbox"/>
	9	02094786	WO		2002-11-28	AstraZeneca AB		<input type="checkbox"/>
	10	02094812	WO		2002-11-28	AstraZeneca AB		<input type="checkbox"/>
	11	03094853	WO		2003-11-20	Ardent Pharmaceuticals Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533744
Filing Date	2005-05-04
First Named Inventor	Brown
Art Unit	1624
Examiner Name	Emily B. Bernhardt
Attorney Docket Number	100886-1P US

12	2004041802	WO		2004-05-21	AstraZeneca AB		<input type="checkbox"/>
13	2004062562	WO		2004-07-29	AstraZeneca AB		<input type="checkbox"/>
14	2006014133	WO		2006-02-09	AstraZeneca AB		<input type="checkbox"/>
15	2006091160	WO		2006-08-31	AstraZeneca AB		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ADRIAENSEN, H. et al., "Clinical Review of Oral Drug Treatments for Diabetic Neuropathic Pain-Clinical Outcomes Based on Efficacy and Safety Data from Placebo-Controlled and Direct Comparative Studies," Diabetes Metab. Res. Rev., 2005, 21(3), pgs. 231-240	<input type="checkbox"/>
	2	BANKER, G. et al., "Modern Pharmaceutics, 3ed.", Marcel Dekker, New York, 1996, pgs. 451 and 596	<input type="checkbox"/>
	3	DAVIS, MP et al., "Controversies in Pharmacotherapy of Pain Management," Lancet Oncol., 2005, 6(9), pgs. 696-704	<input type="checkbox"/>
	4	FILLIOL, D. et al., "Mice deficient for delta- and mu-opioid receptors exhibit opposing alternations of emotional responses," Nature Genetics, 2000, Vol. 25, pgs. 195-200	<input type="checkbox"/>
	5	PRZEWLOCKI, R. et al., "Opioids in Neuropathic Pain," Curr. Pharm. Des. 2005, 11(23), pgs. 3013-3025	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10533744
Filing Date		2005-05-04
First Named Inventor	Brown	
Art Unit		1624
Examiner Name	Emily B. Bernhardt	
Attorney Docket Number		100886-1P US

6	SAITOH, A., "Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents," J. Pharmacol. Sci., 2004, Vol. 95, pgs. 374-380	<input type="checkbox"/>
7	VIPPAGUNTA, S. et al., "Crystalline Solids," Advanced Drug Delivery Reviews, 2001, Vol. 48, pgs. 3-26	<input type="checkbox"/>
8	WEST, A., "Solid State Chemistry and its Applications," Wiley, New York, 1988, pgs. 358 & 365	<input type="checkbox"/>
9	WOLFF, M., "Burger's Medicinal Chemistry and Drug Discovery, 5ed, Part 1," John Wiley & Sons, 1995, pgs. 975-977	<input type="checkbox"/>
10	Copy of International Search Report issued for PCT/SE03/01703 on February 24, 2004	<input type="checkbox"/>
11	Non-final Office Action issued for USSN 10/714447 on September 10, 2004	<input type="checkbox"/>
12	Final Office Action issued for USSN 10/714447 on March 22, 2005	<input type="checkbox"/>
13	Advisory Action issued for USSN 10/714447 on July 5, 2005	<input type="checkbox"/>
14	Non-final Office Action issued for USSN 10/714447 on September 9, 2005	<input type="checkbox"/>
15	Final Office Action issued for USSN 10/714447 on February 16, 2006	<input type="checkbox"/>
16	Non-final Office Action issued for USSN 10/477642 on January 13, 2005	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10533744
Filing Date		2005-05-04
First Named Inventor	Brown	
Art Unit	1624	
Examiner Name	Emily B. Bernhardt	
Attorney Docket Number	100886-1P US	

17	Non-final Office Action issued for USSN 10/477642 on June 15, 2005	<input type="checkbox"/>
18	Final Office Action issued for USSN 10/477642 on November 25, 2005	<input type="checkbox"/>
19	Non-final Office Action issued for USSN 10/477642 on April 6, 2006	<input type="checkbox"/>
20	Non-final Office Action issued for USSN 10/533654 on April 25, 2006	<input type="checkbox"/>
21	Non-final Office Action issued for USSN 10/533654 on December 1, 2006	<input type="checkbox"/>
22	Non-final Office Action issued for USSN 10/533764 on April 17, 2006	<input type="checkbox"/>
23	Final Office Action issued for USSN 10/533764 on October 2, 2006	<input type="checkbox"/>
24	Advisory Action issued for USSN 10/533764 on January 10, 2007	<input type="checkbox"/>
25	Non-final Office Action issued for USSN 11/243623 on December 7, 2005	<input type="checkbox"/>
26	Final Office Action issued for USSN 11/243623 on June 12, 2006	<input type="checkbox"/>
27	Non-final Office Action issued for USSN 11/243623 on August 29, 2006	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533744
Filing Date	2005-05-04
First Named Inventor	Brown
Art Unit	1624
Examiner Name	Emily B. Bernhardt
Attorney Docket Number	100886-1P US

28	Final Office Action issued for USSN 11/243623 on May 17, 2007	<input type="checkbox"/>
29	Non-final Office Action issued for USSN 11/243623 on September 24, 2007	<input type="checkbox"/>
30	Non-final Office Action issued for USSN 11/743824 on September 10, 2007	<input type="checkbox"/>
31	Co-pending US Application No. 10/596851, filed on May 29, 2007, Attorney Docket No. 101260-1P US	<input type="checkbox"/>
32	Co-pending US Application No. 11/572948, filed on January 30, 2007, Attorney Docket No. 101503-1P US	<input type="checkbox"/>
33	Co-pending US Application No. 11/743824, filed on May 3, 2007, Attorney Docket No. 100374-2P US	<input type="checkbox"/>
34	Co-pending US Application No. 11/774935, filed on July 9, 2007, Attorney Docket No. 100883-2P US	<input type="checkbox"/>
35	Co-pending US Application No. 11/816656, filed August 20, 2007, Attorney Docket No. 101692-1P US	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533744
Filing Date	2005-05-04
First Named Inventor	Brown
Art Unit	1624
Examiner Name	Emily B. Bernhardt
Attorney Docket Number	100886-1P US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jacqueline M. Cohen/	Date (YYYY-MM-DD)	2007-09-27
Name/Print	Jacqueline M. Cohen	Registration Number	51574

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.